Haemonetics (HAE) Q2 results came in mixed late yesterday, beating on a per share basis, but...

|About: Haemonetics Corp (HAE)|By:, SA News Editor

Haemonetics (HAE) Q2 results came in mixed late yesterday, beating on a per share basis, but coming up slight shy on the revenue side. Total revenue was up nearly 22% Y/Y however, on continued strength in across its entire product portfolio. Barrington thinks the quarter was strong believes that its integration of PALL is proceeding better than expected. The firm raised its target on the stock to $88 from $79 yesterday and reiterates an Outperform on the stock.